Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Autor: Leighl NB; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Rizvi NA; Department of Hematology and Oncology, Columbia University Medical Center, New York, NY., de Lima LG Jr; Oncoclinicas Group, Hcor Onco, Sao Paulo, SP, Brazil; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD., Arpornwirat W; National Cancer Research, Bangkok, Thailand., Rudin CM; Memorial Sloan Kettering Cancer Center, New York, NY., Chiappori AA; Moffitt Cancer Center, Tampa, FL., Ahn MJ; Department of Hematology and Oncology, Sungkyunkwan University, Seoul, South Korea., Chow LQ; University of Washington, Seattle, WA., Bazhenova L; Department of Clinical Oncology, School of Medicine, UC San Diego Moores Cancer Center, San Diego, CA., Dechaphunkul A; Departments of Pathology, Hematology, and Surgery, Prince of Songkla University, Songkhla, Thailand., Sunpaweravong P; Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand., Eaton K; Prince of Songkla University, Songkhla, Thailand; Medical Oncology at University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA., Chen J; Astellas, Northbrook, IL., Medley S; Astellas, Northbrook, IL., Poondru S; Astellas, Northbrook, IL., Singh M; Astellas, Northbrook, IL., Steinberg J; Astellas, Northbrook, IL., Juergens RA; Juravinski Cancer Centre, Department of Oncology, McMaster University, Hamilton, ON, Canada. Electronic address: juergensr@hhsc.ca., Gadgeel SM; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Hematology-Oncology, Wayne State University, Detroit, MI.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2017 Jan; Vol. 18 (1), pp. 34-42.e2. Date of Electronic Publication: 2016 Aug 08.